Kidney and Blood Pressure Research
Original Paper
Limited Costimulatory Molecule Expression on Renal Tubular Epithelial Cells Impairs T Cell ActivationWaeckerle-Men Y.a · Starke A.a · Wahl P.R.a · Wüthrich R.P.a, baInstitute of Physiology and Zurich Center for Integrative Human Physiology, University of Zürich-Irchel, and bClinic for Nephrology, University Hospital Zürich, Zürich, Switzerland
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: May 15, 2007
Accepted: August 26, 2007
Published online: October 31, 2007
Issue release date: November 2007
Number of Print Pages: 9
Number of Figures: 6
Number of Tables: 0
ISSN: 1420-4096 (Print)
eISSN: 1423-0143 (Online)
For additional information: https://www.karger.com/KBR
Abstract
Background/Aims: MHC molecules are upregulated on renal proximal tubular epithelial cells (TEC) under inflammatory conditions. This allows TEC to act as ‘non-professional’ antigen-presenting cells (APC). The aim of this study was to compare the costimulatory molecule expression pattern and the T cell activation capacity between renal TEC and professional APC, e.g. bone marrow-derived dendritic cells (BM-DC). Methods: Flow cytometry analysis was used to study the costimulatory molecule surface expression on TEC or BM-DC. Ovalbumin-specific CD4 and CD8 T cell activation induced by TEC or BM-DC was compared, in terms of T cell proliferation, cytokine production and CTL activity. Results: TEC did not constitutively express significant amounts of costimulatory molecules. Stimulation of TEC with IFN-β or IFN-γ, but not other tested cytokines, enhanced the expression of PD-L1, ICOS-L and CD40. Compared to BM-DC, TEC only induced suboptimal T cell activation. Blockade of PD-L1 on both APC strongly increased T cell activity. Furthermore, high PD-L1-expressing TEC were more resistant to the cytolysis by CTL. Conclusion: The low costimulatory molecule expression may explain the suboptimal T cell activation by TEC. The IFN-upregulated negative costimulatory molecule PD-L1 on TEC may play a protective role to limit tissue injury during renal parenchymal immune responses.
© 2007 S. Karger AG, Basel
Related Articles:
References
- Rubin-Kelley VE, Jevnikar AM: Antigen presentation by renal tubular epithelial cells. J Am Soc Nephrol 1991;2:13–26.
- Meyers CM: New insights into the pathogenesis of interstitial nephritis. Curr Opin Nephrol Hypertens 1999;8:287–292.
- van Kooten C, Daha MR, van Es LA: Tubular epithelial cells: A critical cell type in the regulation of renal inflammatory processes. Exp Nephrol 1999;7:429–437.
- Greenwald RJ, Freeman GJ, Sharpe AH: The B7 family revisited. Annu Rev Immunol 2005;23:515–548.
- Watts TH: TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005;23:23–68.
- Chen L: Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004;4:336–347.
- Keir ME, Sharpe AH: The B7/CD28 costimulatory family in autoimmunity. Immunol Rev 2005;204:128–143.
- Schoop R, Wahl P, Le Hir M, Heemann U, Wang M, Wuthrich RP: Suppressed T-cell activation by IFN-gamma-induced expression of PD-L1 on renal tubular epithelial cells. Nephrol Dial Transplant 2004;19:2713–2720.
- Wahl P, Wuthrich RP: Role of the B7RP-1/ICOS pathway in renal tubular epithelial antigen presentation to CD4 Th1 and Th2 cells. Nephron Exp Nephrol 2004;98:e31–e38.
- de Haij S, Woltman AM, Trouw LA, Bakker AC, Kamerling SW, van der Kooij SW, Chen L, Kroczek RA, Daha MR, van Kooten C: Renal tubular epithelial cells modulate T-cell responses via ICOS-L and B7-H1. Kidney Int 2005;68:2091–2102.
- Chen Y, Zhang J, Li J, Zou L, Zhao T, Tang Y, Wu Y: Expression of B7-H1 in inflammatory renal tubular epithelial cells. Nephron Exp Nephrol 2006;102:e81–e92.
- Waeckerle-Men Y, Starke A, Wuthrich RP: PD-L1 partially protects renal tubular epithelial cells from the attack of CD8 cytotoxic T cells. Nephrol Dial Transplant 2007;22:1527–1536.
- Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR: T cell receptor antagonist peptides induce positive selection. Cell 1994;76:17–27.
- Wuthrich RP, Glimcher LH, Yui MA, Jevnikar AM, Dumas SE, Kelley VE: MHC class II, antigen presentation and tumor necrosis factor in renal tubular epithelial cells. Kidney Int 1990;37:783–792.
- Waeckerle-Men Y, Gander B, Groettrup M: Delivery of tumor antigens to dendritic cells using biodegradable microspheres. Methods Mol Med 2005;109:35–46.
- Singer GG, Yokoyama H, Bloom RD, Jevnikar AM, Nabavi N, Kelley VR: Stimulated renal tubular epithelial cells induce anergy in CD4 T cells. Kidney Int 1993;44:1030–1035.
- Frasca L, Marelli-Berg F, Imami N, Potolicchio I, Carmichael P, Lombardi G, Lechler R: Interferon-gamma-treated renal tubular epithelial cells induce allospecific tolerance. Kidney Int 1998;53:679–689.
- Lang KS, Recher M, Junt T, Navarini AA, Harris NL, Freigang S, Odermatt B, Conrad C, Ittner LM, Bauer S, Luther SA, Uematsu S, Akira S, Hengartner H, Zinkernagel RM: Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 2005;11:138–145.
- Hagerty DT, Evavold BD, Allen PM: Regulation of the costimulator B7, not class II major histocompatibility complex, restricts the ability of murine kidney tubule cells to stimulate CD4 T cells. J Clin Invest 1994;93:1208–1215.
- Wahl P, Schoop R, Bilic G, Neuweiler J, Le Hir M, Yoshinaga SK, Wuthrich RP: Renal tubular epithelial expression of the costimulatory molecule B7RP-1 (inducible costimulator ligand). J Am Soc Nephrol 2002;13:1517–1526.
- Blank C, Gajewski TF, Mackensen A: Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 2005;54:307–314.
- Rini BI: Current status and future directions of molecular markers in renal cell carcinoma. Curr Opin Urol 2006;16:332–336.
-
Dong H, Chen X: Immunoregulatory role of B7-H1 in chronicity of inflammatory responses. Cell Mol Immunol 2006;3:179–187.
External Resources
- Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH: Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med 2006;203:2223–2227.
- Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon ED: Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66:3381–3385.
- Nishimura H, Nose M, Hiai H, Minato N, Honjo T: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141–151.
- Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, Klemm M, Kuchroo VK, Freeman GJ, Sharpe AH: PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci USA 2004;101:10691–10696.
- Koga N, Suzuki J, Kosuge H, Haraguchi G, Onai Y, Futamatsu H, Maejima Y, Gotoh R, Saiki H, Tsushima F, Azuma M, Isobe M: Blockade of the interaction between PD-1 and PD-L1 accelerates graft arterial disease in cardiac allografts. Arterioscler Thromb Vasc Biol 2004;24:2057–2062.
- Sandner SE, Clarkson MR, Salama AD, Sanchez-Fueyo A, Domenig C, Habicht A, Najafian N, Yagita H, Azuma M, Turka LA, Sayegh MH: Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol 2005;174:3408–3415.
- Gao W, Demirci G, Strom TB, Li XC: Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival. Transplantation 2003;76:994–999.
Article / Publication Details
Received: May 15, 2007
Accepted: August 26, 2007
Published online: October 31, 2007
Issue release date: November 2007
Number of Print Pages: 9
Number of Figures: 6
Number of Tables: 0
ISSN: 1420-4096 (Print)
eISSN: 1423-0143 (Online)
For additional information: https://www.karger.com/KBR
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
